Novel molecular targets in gastric adenocarcinoma
| Autor: | Roya Ramezankhani, Massoud Vosough, Hamidreza Aboulkheyr Es, Moustapha Hassan, Roya Solhi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Biology Adenocarcinoma Chromatin remodeling Epigenesis Genetic 03 medical and health sciences 0302 clinical medicine Stomach Neoplasms medicine Humans Pharmacology (medical) Epigenetics Pharmacology & Pharmacy EZH2 Pharmacology Histone Demethylases Cancer medicine.disease Phenotype Chromatin 030104 developmental biology Histone PCAF 030220 oncology & carcinogenesis Cancer research biology.protein 1115 Pharmacology and Pharmaceutical Sciences Gastric cancer Histone modification |
| Popis: | Gastric adenocarcinoma (GAC) is the third leading cause of cancer-related death worldwide. A high mortality rate and resistance to treatment protocols due to a heterogeneous molecular pathogenesis has made discovering the key etiologic molecular alterations of the utmost importance. The remarkable role played by epigenetic modifications in repressing or activating many cancer-related genes and forming new epigenetic signatures can affect cancer initiation and progression. Hence, targeting the key epigenetic drivers could potentially attenuate cancer progression. MLLs, ARID1A and EZH2 are among the major epigenetic players that are frequently mutated in GACs. In this paper, we have proposed the existence of a network between these proteins that, together with PCAF and KDM6A, control the 3D chromatin structure and regulate the expression of tumor suppressor genes (TSGs) and oncogenes in GAC. Therefore, we suggest that manipulating the expression of EZH2, PCAF, and KDM6A or their downstream targets may reduce the cancerous phenotype in GAC. ispartof: PHARMACOLOGY & THERAPEUTICS vol:220 ispartof: location:England status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|